Abbreviations: CR, complete response; ORR, objective response rate; PR,... | Download Scientific Diagram
Simplifying the Derivation of Best Overall Response per RECIST 1.1 and iRECIST in Solid Tumor Clinical Studies
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer | NEJM
Development of an algorithm for evaluating the impact of measurement variability on response categorization in oncology trials | BMC Medical Research Methodology | Full Text
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial
The overall response rate | Download Table
Efficacy endpoints in Oncology
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Best Overall Response and Time to Response | Download Table
Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect
KAZIA PRESENTS FURTHER PAXALISIB AND CANTRIXIL DATA AT AACR, REINFORCING POSITIVE EFFICACY SIGNALS FOR BOTH DRUGS
Starting with higher-dose prednisone boosts 1-year renal response in lupus nephritis
Clinical Trial Endpoints for Oncology Studies
Overall vs. Progression-Free Survival, Response Rates: Oncology Terminology 101 (by Oster Oncology) - YouTube
For personal use only
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses | Journal of Clinical Oncology
Iovance Biotherapeutics: The Frontier Of Novel Cancer Treatment (NASDAQ:IOVA) | Seeking Alpha
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Efficacy endpoints in Oncology
